• Dogwood Therapeutics highlighted Halneuron injection for chemotherapy-induced neuropathic pain, targeting a Phase 2b data readout in fall 2026.
• Milestones include a Q4 2026 end-of-Phase 2 FDA submission for Halneuron in CINP.
• Phase 2b interim analysis set a 210-240 patient sample size to maintain 80%-85% power, citing an efficacy signal versus placebo.
• Pipeline update flagged SP16 IV in CIPPN with an FDA-accepted IND, with Phase 1b enrollment slated to start in Q3 2026.
• Corporate snapshot showed USD 13.2 million cash as of March 31, 2026 pro forma, with 33,629,553 shares outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.